New startup ideas · Health and bio · Healthcare and bio
startup idea
Cytebench
A cGMP cell therapy production pod inside community oncology clinics, with an open protocol API.
Cytebench builds a closed, room-temperature benchtop system that manufactures autologous cell therapy doses at the point of care, and exposes the run as an API so therapy developers can publish validated protocols onto it.
- Infrastructure and APIs
- Small business
- $10-100B market
- Platform others build on
- US first
3/5
venture judge
6
similar startups, last 2 years (85 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$3,000 · 6 weeks · 15 prospects
For $3,000 in 6 weeks, prove that community oncology practice owners will sign up in writing to become FDA-inspectable manufacturing sites, and that at least one sponsor will fund a protocol slot on paper.
Riskiest assumption · The owner of an independent community oncology practice will commit the practice in writing to become an FDA-inspectable manufacturing site, with the space, trained staff and audit exposure that entails, in exchange for keeping cell therapy patients and their episode revenue in-house.
1Focus group: who and where
Managing partner or practice administrator of an independent community oncology practice with 5-25 physicians and a working biologic infusion suite, who this quarter referred CAR-T-eligible patients to an academic center 100 miles away and watched the entire episode's revenue leave with them.
where to find 15 · Community Oncology Alliance (COA) membership, the association these independent practices actually belong to; the public CMS Enhancing Oncology Model participant list, which names community practices state by state for the call list; the ACCC National Oncology Conference in the fall, where practice administrators show up; for the sponsor side, the Alliance for Regenerative Medicine member list and its Meeting on the Mesa in October.
2Sell first, build later
A founding-site partnership sold on paper: the practice is named one of 6 launch sites for point-of-care cell therapy manufacturing, hosts the first sponsor-funded protocol under an investigational site amendment with Cytebench staff on site for every run in year one, with first installation targeted 18 months out and contingent on FDA clearance.
the ask · $0 moves now; the clinic LOI commits a dedicated 120 sq ft space and a named PI against a per-run fee capped at $8,000, and the sponsor LOI commits a funded protocol slot of $50,000 or more
a real yes · A real yes is a countersigned LOI with a named PI, a dated site-readiness commitment and partnership sign-off, or a sponsor LOI with a dollar amount; 'fascinating, keep us posted', nurse enthusiasm without the managing partner, and sponsor interest with no funded amount are not a yes.
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Site-commitment calls with owners
$300 · 21 days
Write a two-page site prospectus that states the hard parts plainly: dedicated 120 sq ft, trained staff, FDA inspection exposure, per-run fee capped at $8,000, against the $40,000+ episode revenue a retained patient keeps in the practice. The founder books 15 calls through COA contacts and direct email to Enhancing Oncology Model practices, walks each owner through it, and asks for a founding-site LOI on the call.
keep going if · 6 of 15 owners still ask for the LOI after hearing the FDA inspection requirement out loud, and at least 4 name the physician who would be principal investigator
2. Sponsor protocol-slot LOIs
$200 · 21 days
Run 10 calls with autologous cell therapy developers found through the Alliance for Regenerative Medicine member list and outreach at Meeting on the Mesa, including teams like Gamgee and FinalDose named on the card. Offer a founding protocol slot: their protocol published to the first 6 community sites, with a funded amount and a first-patient window in the LOI.
keep going if · 3 of 10 sponsors sign an LOI naming a protocol and a funded amount of $50,000 or more for a first decentralized site
3. Regulatory precedent memo
$2,500 · 14 days
Engage a former FDA CBER reviewer or CGT regulatory consultant for a 10-hour scoped engagement: map whether one application can cover multiple point-of-care sites under FDA's distributed manufacturing framework discussions, and estimate per-site regulatory cost. The memo is shown to clinics and sponsors in the same 6 weeks.
keep going if · The memo cites at least 2 precedents of multi-site autologous manufacturing under a single application and estimates per-site cost under $250,000
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$0
no cash yet: take a signed commitment
how · No money can credibly move: a clinic cannot buy manufacturing runs before FDA clearance and site inspection, so collect signed instruments instead. From clinics, an LOI with a named principal investigator, a reserved 120 sq ft space and partnership sign-off; from sponsors, an LOI naming the protocol, the funded slot amount and an intended first-patient window; the founder countersigns both.
what it reserves · One of 6 founding-site slots at locked launch pricing for clinics, and first access to the installed base for the sponsor
refund · The LOI is non-binding and either side may withdraw in writing at any time before a definitive agreement.
target · 4 clinic LOIs from 15 practices and 1 sponsor LOI with a funded amount, within 6 weeks
before taking money · Nothing may be manufactured, administered or presented to clinics as available to patients before FDA clearance and site licensure; keep every commitment on paper only and put regulatory counsel across the LOIs before sponsors sign.
Go: build it if
4 of 15 practices sign LOIs with named PIs, at least 1 sponsor signs a protocol LOI funded at $50,000 or more, and the regulatory memo finds multi-site precedent with per-site cost under $250,000.
Kill: stop if
Fewer than 3 clinic LOIs after 15 owner conversations, zero funded sponsor LOIs from 10 calls, or a memo showing every clinic needs its own pre-approval inspection at $500,000 or more per site.
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
Your practice runs biologics every day, but every CAR-T-eligible patient you diagnose gets referred out, and the whole episode leaves with them. I am signing 6 founding sites for a benchtop system that manufactures autologous doses inside the clinic, starting with one sponsor-funded protocol and our team on site for every run. Before anything is built, I want your read on the site requirements, FDA inspection included. Do you have 20 minutes this week?
landing page
Keep cell therapy patients, and their episodes, in your practice No payment now; a founding-site LOI reserves 1 of 6 launch slots. Request the site prospectus.
deposit terms
Signing reserves one of 6 founding launch sites at locked launch pricing, with no payment due before FDA clearance and your site's readiness review. The LOI is non-binding and you may withdraw in writing at any time. Target first installation is 18 months from signature, contingent on FDA clearance.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
66
Idea Score, 0-100 · raw 41.0 x 1.61
Active
competition: more crowded than 65% of ideas · headwind x0.67
+4.9
government priorities, secondary (184 matching grants)
Trend
54
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)21
- Rounds announced 2025+ in the sector69
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
52
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain25
100x potential
56
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge50
- Market size axis67
- Moat axis20
- Neighbours still alive47
- Technologist judge100
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were cgmp, cell, therapy, production, pod, community, oncology, builds.
The idea in full
- What
- Cytebench builds a closed, room-temperature benchtop system that manufactures autologous cell therapy doses at the point of care, and exposes the run as an API so therapy developers can publish validated protocols onto it. The buyers are independent community oncology practices and small infusion centers that cannot ship patients to an academic center. Clinics pay per run; sponsors pay for protocol slots, which is the platform layer others build on.
- Why now
- Gamgee (yc S26) is pitching scalable personalised cancer treatment and FinalDose (yc X26) a programmable DNA cancer drug in the same two cohorts, while Ambrosia Biosciences took a $100M Series B on 2026-03-31, so the therapies exist and the bottleneck has moved to where doses get made.
- Wedge: first customer and entry point
- Six community oncology practices already running biologic infusions, starting with a single sponsor-funded protocol under an investigational manufacturing site amendment, with the founding team on site for the first runs.
- Path to 100x
- Cell and gene therapy manufacturing is a $10-100B market currently locked to a handful of centralized facilities, and moving production to the clinic collapses the cost and the vein-to-vein time that limits patient volume. If sponsors publish protocols onto the installed base to reach community patients, the pod becomes the distribution channel for an entire therapy class.
- Ceiling
- There is no moat yet: a large contract manufacturer or an instrument maker can copy the pod once the regulatory path is proven, and hardware alone does not hold the sponsors.
- Closest real companies, as the generator saw them
- Ruma Care (yc W26) builds the operations stack for biologic infusion clinics but stays in software; AbInitio Bio (yc X26) is an intelligence layer for drug manufacturing, not the machine. Cytebench is the physical production unit those layers would sit on top of.
- Main risk
- FDA treats every clinic as a separate manufacturing site requiring its own inspection, and the per-site regulatory cost never amortizes.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
3/5
A $10-100B category-defining distribution channel, but the card admits no moat and FDA may inspect every clinic as a separate site.
Bootstrapper
1/5
FDA may inspect every clinic as a separate manufacturing site, so per-site regulatory cost never amortizes on a capital-heavy pod.
Operator
2/5
Community oncology practices must become inspected manufacturing sites to benefit, a workflow change no clinic owner wants at per-site FDA cost.
Technologist
5/5
A closed room-temperature benchtop system manufacturing autologous doses at the point of care is among the hardest builds here, moat or not.
Risk
1/5
No moat plus FDA likely inspecting each of six community oncology clinics as a separate manufacturing site, with sponsors free to leave anytime.
trends
2/5
Point-of-care cell therapy pods cite funded therapies but no FDA change dated 2025-2026, and the card admits per-site inspection economics are unresolved.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (cgmp, cell, therapy, production, pod, community, oncology, builds): 85 all-time, 6 from the last two years. Same matching as Idea Check.
Supercharging existing cancer therapies.
Using protein coupling to build new therapies
Living therapies for pets first, and their people next
Core Biogenesis is a biotechnology company building next-generation recombinant protein production technologies.
AI-native retrieval engine for medical records
Robotic pitstops for self-driving cars
OmniSpirant develops regenerative gene therapies with game changing innovation in respiratory medicine and oncology.
We Handle AI. You Direct Films.
Serenity Power drives the clean energy transition using advanced Solid Oxide Fuel Cell (SOFC) technology, focusing on decarbonizing complex industries.
Genomate Health is a digital health company that develops computational (AI) solutions for personalized medicine.
Turn the web into structured data
To move goods more like we do information.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1595
startup-relevant grants in Healthcare and bio
$854M
awarded in the sector, tracked
118
opportunities open now in the sector
- Cardiovascular Safety and Scalable Manufacturing for Investigational New Drug Filing of a Novel Oral Drug to Accelerate Musculoskeletal Recovery in Older Adultsawardhigh relevance
NIH / NIA · SBIR phase II · $2M · posted 2026-09-23
- Overcoming Immune Evasion in Hepatocellular Carcinoma with Engineered T-Cell Therapyawardhigh relevance
NIH / NCI · SBIR phase II · $399K · posted 2026-09-22
- RadBot: Next-Generation Drug Discovery for Environmental Stress Resistance Using Longevity Biologyawardhigh relevance
NIH / NIA · SBIR phase I · $300K · posted 2026-09-22
- Gut-Targeted IL-10 Delivery via Engineered Saccharomyces boulardii to Prevent Immune Checkpoint Inhibitor Colitisawardhigh relevance
NIH / NIDDK · SBIR phase II · $372K · posted 2026-09-21
NIH / NCI · SBIR phase II · $1M · posted 2026-09-17
- Development of a Dual-Action Oral Immunotherapy for Clostridioides difficile Preventionawardhigh relevance
NIH / NIAID · SBIR phase II · $313K · posted 2026-09-11
NIH / NCI · SBIR phase II · $307K · posted 2026-09-03
NIH / NIAID · SBIR phase I · $302K · posted 2026-09-01
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 121 → 224 → 173 → 127 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 442 YC companies here: 6 acquired, 6 shut down, 45 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Small business
- Business model
- Infrastructure and APIs
- Path to 100x
- Platform others build on
- Market size
- $10-100B market
- Capital intensity
- Capital-heavy (hardware, bio, infra)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Partners and channels
- Moat
- No moat yet
- Geography
- US first
- Regulation
- Heavily regulated
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.